NIH clinical trial of universal flu vaccine candidate begins A colorized transmission electron micrograph of influenza A virus particles, colorized orange, isolated from a patient sample and then propagated in cell culture. ©NIAID Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at…..
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform AstriVax will draw on technology developed at the KU Leuven Rega Institute (Belgium) to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various pathogens. Closing on…..
EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles EUROAPI, the European CDMO announced by Sanofi in February 2020, has expanded its collaboration with the French group under the umbrella of their Master Agreement for Development and GMP Manufacturing Services, dated October 1, 2021, to support…..
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France Boehringer Ingelheim announced an additional €100 million investment in its veterinary public health capabilities in Lyon-Jonage, France, to aid governments and public health organizations in managing future emerging and transboundary diseases. Transboundary and emerging diseases are…..
A 100% French nasal vaccine against COVID-19 yields positive pre-clinical results In contrast to intramuscular vaccines, only nasal vaccines are able to block the virus in the nose by inducing local immunity in the nasal mucosa, i.e. the portal of entry and multiplication of the virus. The vaccine candidate, developed…..
Evonik delivers first lipids from German facility to BioNTech The German company Evonik is delivering first batches of urgently needed lipids used in production of COVID-19 vaccine to BioNTech on April 22. Initially, delivery was scheduled to start in the middle of the year. But, specialists at Evonik’s Hanau site…..
Celonic will manufacture over 100 million doses of Curevac's COVID-19 Vaccine Candidate, CVnCoV CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020 and CVnCoV is the vaccine candidate chosen for…..
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases ConserV Bioscience, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA, a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its TriMix technology,…..
